Related Experiment Video
Updated: Jan 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with
Amrita Goyal1, Sanjay Patel2, Kavita Goyal1
1Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
Aims:
Brentuximab vedotin is a monoclonal anti-CD30 antibody-drug conjugate that has been used to treat a variety of CD30+ neoplasms. The phenomenon of antigen loss has been observed in patients treated with the anti-CD20 antibody rituximab. This study seeks to assess for antigen loss in the setting of recurrent CD30+ neoplasms treated with brentuximab vedotin.
Methods:
We report nine cases of persistent/recurrent cutaneous CD30+ lymphoid neoplasms that demonstrated variable CD30 expression after treatment with brentuximab vedotin. Cases include MF (n = 6), cutaneous T-cell lymphoma, not otherwise specified (n = 1), and anaplastic large cell lymphoma (ALCL), both primary (n = 1) and systemic (n = 1).
Results:
Immunohistochemical staining revealed decreased CD30 expression following brentuximab vedotin therapy in seven of nine cases. In these seven cases, the pre-treatment percent of tumor cells staining for CD30 ranged from 10% to 100% (mean 50.0%, SD 27.8%), compared to 5% to 50% (mean 14.5%, SD 14.8%, P = 0.003) at recurrence.
Conclusions:
This case series highlights the finding that CD30 positivity can be variable in recurrences after treatment with anti-CD30 antibodies. This serves to raise awareness of the phenomenon of antigen loss after treatment with brentuximab vedotin and underscores the utility of performing multiple biopsies and/or employing molecular diagnostic techniques in patients with recurrent/persistent disease.
Insights
Brentuximab vedotin treatment can lead to CD30 antigen loss in recurrent CD30+ neoplasms. This antigen loss may affect treatment efficacy and necessitates careful monitoring of persistent disease.
Area of Science:
- Oncology
- Immunotherapy
- Dermatology
Background:
- Brentuximab vedotin is an anti-CD30 antibody-drug conjugate used for CD30+ neoplasms.
- Antigen loss is a known issue with antibody therapies, such as anti-CD20 rituximab.
Observation:
- This study investigated antigen loss in nine patients with recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
- The cases included mycosis fungoides, unspecified cutaneous T-cell lymphoma, and anaplastic large cell lymphoma.
Findings:
- Seven out of nine patients showed decreased CD30 expression after brentuximab vedotin therapy.
- Pre-treatment CD30 expression averaged 50.0%, decreasing to 14.5% at recurrence (P = 0.003).
Implications:
- CD30 positivity can be variable in recurrent CD30+ neoplasms post-brentuximab vedotin treatment.
- Awareness of antigen loss is crucial; multiple biopsies and molecular diagnostics are recommended for persistent disease.
Related Concept Videos
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Variables Affecting Phosphorescence and Fluorescence

